SAN DIEGO–(BUSINESS WIRE)–San Diego-based Clarify Medical has announced the appointment of George W. Mahaffey as President, Chief Executive Officer and Director. The position had been filled by Rex Bright who was named interim President and CEO in February 2018. Mr. Bright will continue to serve on the Board of Directors for the company. Executive Chairman….
–Technology Powers Home-Based System Targeted at the Treatment of Psoriasis and Vitiligo– SAN DIEGO–(BUSINESS WIRE)–Clarify Medical, developer of the Clarify Medical® Home Light Therapy System, a software-controlled home phototherapy system for the treatment of psoriasis, vitiligo, eczema, and other skin conditions, today announced that the United States Patent and Trademark Office has issued US patent 9,9913,993, entitled….
SAN DIEGO–(BUSINESS WIRE)–Clarify Medical, developer of the Clarify Medical® Home Light Therapy System, a software-controlled home phototherapy system for the treatment of psoriasis, vitiligo, and eczema, today announced that the United States Patent and Trademark Office has issued US patent 9,901,747, entitled “Phototherapy Light Engine.” The patent covers a precision, targeted phototherapy device using UVB LEDs,….
SAN DIEGO–(BUSINESS WIRE)–Clarify Medical will introduce the Clarify Medical® Home Light Therapy System, an FDA-cleared home phototherapy system for the treatment of psoriasis, vitiligo, and eczema at the American Academy of Dermatology Annual Meeting in San Diego later this week. The Clarify System is the first and only phototherapy system that uses an app on the….
SAN DIEGO–(BUSINESS WIRE)–San Diego-based Clarify Medical, the developer and marketer of Clarify Medical™ Home Light Therapy System, announced today that its CEO Jim Sweeney has resigned for health reasons. Rex Bright, a current Board member of Clarify Medical, has agreed to serve as interim President and CEO until the company is prepared to announce a….
SAN DIEGO–(BUSINESS WIRE)–San Diego-based Clarify Medical’s Home Light Therapy System, an FDA-cleared home-based treatment technology for vitiligo, is now available nationwide. During a usage trial, vitiligo patients utilizing the lightweight home-based system experienced noticeable improvement (including re-pigmentation), some within as little as three weeks. The Clarify System allows convenient home phototherapy linking patient, physician and Clarify….
SAN DIEGO–(BUSINESS WIRE)–San Diego-based Clarify Medical, the developer and marketer of the Clarify Medical™ Home Light Therapy System, announced today that its FDA-cleared home-based treatment technology for psoriasis and vitiligo is now rolling out for national distribution. The lightweight Clarify system allows convenient home phototherapy linking patient, physician and Clarify CarePartner through Android and IOS smartphones….
San Diego medtech startup Skylit Medical has changed its name to Clarify Medical and brought in local executive James M. Sweeney as its new CEO. Sweeney is taking the reins from Martyn Gross, the company’s founder and CEO for the past two years. Gross, 33, will stay on as the company’s VP of innovation. “Martyn….
Narrowband ultraviolet B (NB-UVB) phototherapy is an effective treatment for vitiligo, resulting in up to 75% repigmentation in 9 months; however, compliance is often poor due to the economic burden and inconvenience associated with this form of therapy. Home phototherapy has been shown to be an effective treatment for a variety of skin conditions, including….
The economic burden of psoriasis is substantial. It is important to consider the costs to the healthcare system over a patient’s lifetime when they start biologics or home phototherapy. Phototherapy is an effective and economical option for the treatment of moderate to severe plaque psoriasis.
Atopic dermatitis can usually be controlled with appropriate skin care and topical steroids or topical calcineurin inhibitors. However, more severe disease can disrupt the life of a child and his or her family. All too often, parents receive repeated courses of systemic steroids, which can cause HPA axis suppression and growth retardation. Systemic immunosuppressives also….
Atopic dermatitis (AD) is a common chronic inflammatory skin disease that can affect all age groups. Phototherapy represents a valid second-line intervention in those cases where non-pharmacological and topical measures have failed. This review illustrates the main trials comparing the efficacy and safety of the different forms of phototherapy. Clinicians mainly refer to the indications….
Atopic dermatitis is a chronic, pruritic inflammatory dermatosis that affects up to 25% of children and 2% to 3% of adults. This guideline addresses important clinical questions that arise in atopic dermatitis management and care, providing recommendations based on the available evidence. In this third of 4 sections, treatment of atopic dermatitis with phototherapy and….
Vitiligo is a depigmenting skin disorder with an estimated prevalence of 1%. Childhood-onset vitiligo occurs in approximately a third of all cases. Early-onset childhood vitiligo tends to be a more extensive and progressive type of vitiligo. Narrowband ultraviolet-B (NB-UVB) phototherapy is an effective treatment option in active vitiligo and leads to >75% repigmentation in 14-75%….
While phototherapy is a treatment of choice for vitiligo, it is time consuming and generally carried out in a health institution. This study compared home-based phototherapy with institution-based excimer. The home based phototherapy group had better efficacy with 72% and 50% in the group achieving good and excellent repigmentation, respectively, in contrast to only 54%….
Narrowband ultraviolet B light (NBUVB) is an important component of the standard of care in vitiligo treatment. However, there are no consistent guidelines regarding the dosing and administration of NBUVB in vitiligo. In this study, experts in vitiligo treatment make broad recommendations to assist dermatologists in the treatment of vitiligo with NBUVB phototherapy.
The efficacy and safety of biologic and phototherapy in treating moderate-to-severe psoriasis is well known. However, some patients may not respond well to biologic agents or phototherapy on their own and may require combination therapy. Skillfully combining a biologic agent and phototherapy may provide an additive improvement without much increase in risks. This study summarizes….
Narrow-band ultraviolet B (NB-UVB) phototherapy is a widely used treatment. Psoralen-UVA photochemotherapy (PUVA) increases skin cancer risk and some animal studies have raised the possibility of an increased risk with NB-UVB. This study assessed the effect of NB-UVB exposure treatment numbers on the risk of developing skin cancer. No significant association between NB-UVB treatment and….
Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In this fifth of 6 sections of the guidelines of care for psoriasis, we discuss the use of ultraviolet (UV) light therapy for the treatment of patients with psoriasis. Treatment should be tailored to meet….